PMH1 The Economic Burden of Schizophrenia: Acute General Hospital Costs  by O'Brien, JA et al.
78
ECONOMIC AND OUTCOMES ISSUES IN
MENTAL HEALTH AND NEUROLOGIC
DISORDERS
PMH.
THE ECONOMIC BURDEN OF SCHIZOPHRENIA:
ACUTE GENERAL HOSPITAL COSTS
O'Brien jA, Shomphe LA, Pietrusewicz Mj, Caro JJ
Caro Research, Concord, MA, USA
In the U.S., acute general hospitals increasingly provide
treatment for patients with schizophrenia.
OBJECTIVE: To estimate the average annual cost of in-
patient schizophrenia care per patient in an acute general
hospital setting.
METHODS: Using ICD9 codes to identify disease and
procedure-level data in five state (CA, FL, MA, MD, NC)
acute care, all payer, discharge databases, an average cost
per admission was estimated and combined with the fre-
quency of admission calculated from the MA database to
derive a mean annual acute care inpatient cost. Physician
costs were calculated by applying 1997 Medicare fees to
a resource use profile derived from the databases and
published treatment recommendations. All costs are re-
ported in 1997 US$, appropriately adjusted for medical
inflation and cost-to-charge ratios.
RESULTS: Of 7.5 million discharges, 73,000 were identi-
fied as having been admitted primarily due to schizophre-
nia. The average length of stay was 13.5 days, with 90%
of time spent in a designated psychiatric bed. Over 90%
were discharged within one month, most (rv80%) to
home without documentation of further services. The
mean cost per stay (including physician fees) was $8,963.
Most (68%) patients had only one admission, and 96%
had less than five in one year, leading to an annual hospi-
talization cost per schizophrenic patient of $13,854.
CONCLUSIONS: Of schizophrenic patients admitted to
an acute general hospital, the majority are admitted only
once per year, spend their stay in a designated psychiatric
unit bed, and are discharged within two weeks. Although
these patients may have subsequent admissions to an-
other type of inpatient facility, the majority are not trans-
ferred to such a facility at the time of discharge.
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ASSESSMENT OF HEALTH-RELATED QUALITY
OF LIFE DURING TREATMENT OF OPIATE
DEPENDENCE USING THE SHORT FORM·36
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OBJECTIVE: To determine if quality of life, as measured
by the Short Form-36 (SF-36), improved during the treat-
ment of opiate dependence and to identify which dimen-
sions of the SF-36 were impacted by treatment.
METHODS: The SF-36 was administered via computer
to 100 patients enrolled in a clinical trial of a new drug
for opiate dependence. The trial compared two dosage
forms of the drug. The five time points for administration
were upon enrollment (T1) and monthly (T2-T5) for the
16-week trial. The study was conducted at a drug abuse
treatment clinic in a large metropolitan area. Data were
analyzed using paired t-tests.
RESULTS: Significant improvement in health-related qual-
ity of life (P < .013, one tailed) occurred in the dimen-
sions of bodily pain (T3, T4 > T1), general health (T2,
T3 > T1), mental health (T2, T3, T5 > T1), social func-
tion (Tl, T3, T4, T5 > Tl), and vitality (T3, T4, T5 >
T1 and T3 > T2). Changes in measures of physical func-
tioning and role physical dimensions were not affected by
addiction treatment. Changes in general health, mental
health, and social function occurred between the enroll-
ment assessment and the first month of treatment (T1
versus T2). However, significant improvement in bodily
pain and vitality did not occur until the second month
and after (T1 versus T3-T5).
CONCLUSION: Quality of life measures improved dur-
ing opiate dependence treatment. Fewer measures of
physical dimensions improved than mental dimensions.
The SF-36 was sensitive to improvements in quality of life
in patients treated for opiate dependence; therefore it was
helpful in measuring patient outcomes.
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EVALUATION OF HUMANISTIC OUTCOMES
FOR PATIENTS ON SELECTIVE SEROTONIN
REUPTAKE INHIBITORS
Sansgiry SS', Burgoyne OS', BusbyCf
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Patient-centered outcomes are very important to health
plans. Satisfaction with pharmacy/prescription benefits
and patients health status are two such outcomes that
managed care organizations consider consequential.
OBJECTIVE: The purpose of this study was to examine
the relationship between general health status and satis-
faction with pharmacy benefits for patients taking selec-
tive serotonin reuptake inhibitors (SSRIs). Additionally,
